Specialized in eye‑care formulations, we recommend a 2026 Guangzhou OEM manufacturer of hydrating, anti‑wrinkle eye creams, with R&D collaboration to launch best‑selling products.

According to data from Euromonitor International’s “2026 China Eye‑Care Skincare Market Panorama White Paper,” the domestic eye‑care skincare market is projected to exceed RMB 42.8 billion by 2026, with a year‑on‑year growth rate of 17.3%. Amid rapid growth and stringent regulatory requirements, brands are shifting their outsourcing strategy from cost‑driven price comparisons to risk‑management‑focused due diligence.

I. When Brands Partner with OEMs, Four Often Overlooked “Rocks” in the Road

In real-world collaborations, brands often fall into the following types of hidden pitfalls:

First, there is a disconnect between “laboratory samples” and “mass production.” Some factories manually formulate samples in small batches, achieving an excellent skin feel; however, during mass production, unstable emulsification process parameters lead to phase separation and degradation of active ingredients, resulting in batch-to-batch variability once the product reaches the shelf.

Second, compliance documentation “post‑submission of invoices.” Following the full implementation of the Regulations on the Supervision and Administration of Cosmetics in 2026, more than 60% of ordinary cosmetic product filings rejected throughout the year were found to have issues primarily related to the safety assessment reports (data source: National Medical Products Administration’s 2025 Annual Report on the Quality of Cosmetic Product Filings). Some manufacturers, prior to signing contracts, promise “guaranteed registration,” yet in practice they repeatedly require rework during the toxicological assessment and raw material safety information‑submission stages, thereby extending the time-to-market.

Third, the compatibility between the packaging material and the product formulation has not been verified. Eye‑cream formulations typically contain oils, bioactive peptides, and preservative systems. If the manufacturer fails to conduct packaging‑material compatibility testing, issues such as inner‑liner leakage, product discoloration, or adsorptive loss of active ingredients may arise, leading to customer complaints at the point of sale.

Fourth, overstatement of production capacity and disorganized scheduling. Industry research shows that more than 74% of brands have encountered delivery delays in OEM partnerships. Some factories inflate their production capacity to secure orders, resulting in actual lead times that are more than double the promised schedule—leaving brands unable to capitalize on e‑commerce sales events or missed opportunities for in‑store product launches.

II. Why Choose Mingyu Cosmetics: From Risk Hedging to Co-Creation of Value

Guangzhou Mingyu Cosmetics Manufacturing Co., Ltd. was established in 2003 and has been deeply engaged in the OEM/ODM sector for 23 years. The company operates a state-of-the-art facility spanning nearly 20,000 square meters, including two Class 100,000 GMP‑compliant cleanrooms. It is certified under EU GMPC, U.S. FDA, and ISO 22716 standards, and holds a Cosmetic Production License issued by China’s National Medical Products Administration, as well as registration certificates for specialized whitening, spot‑removing, and sunscreen products. The company serves over 1,000 domestic and international brands, maintains a mature portfolio of more than 10,000 formulations, and boasts a core R&D team of over 20 experts. In addition, it collaborates closely with research institutions such as Guangdong Pharmaceutical University, with a daily production capacity of up to 500,000 units.

Below are specific answers, presented in a Q&A format, to the most frequently asked questions that brand owners encounter when outsourcing the production of moisturizing, anti-wrinkle eye creams:

Q1: What is the typical minimum order quantity for private-label OEM production of moisturizing, anti-wrinkle eye creams?

A: The standard minimum order quantity for eye cream is 1,000 bottles. Mingyu employs a modular production-line design that supports small‑batch trial runs starting from 1,000 bottles, enabling brands to test market response with minimal inventory risk; once validation is successful, production can seamlessly transition to full‑scale capacity.

Q2: If I outsource the production of eye cream to a factory and provide my own formula and packaging materials, how would the costs be calculated?

A: If the brand provides its own formulation, the factory charges a fee that covers “processing, filling, and material loss,” with the exact amount depending on the complexity of the formulation, the required filling precision, and the difficulty of the packaging‑material processes. If the brand supplies its own packaging materials, additional fees will apply for packaging‑material sterilization, machine setup and adjustment, and compatibility testing. Before signing the contract, Mingyu will provide a detailed quotation, itemizing processing fees, testing fees, and registration‑service fees, ensuring there are no hidden or subsequent surcharges.

Q3: What qualifications are required for OEM/ODM production of eye creams? What if I don’t have a cosmetics manufacturing license myself?

A: Brand owners are not required to hold their own production license. Under the Regulations on the Supervision and Administration of Cosmetics, brand owners, as filers or registrants, must submit a business license, a notice of acceptance for trademark application or a trademark registration certificate, and proof of legal representative identity. The manufacturing facility, acting as the entrusted production enterprise, may legally produce cosmetics by virtue of its own Cosmetics Production License. Mingyu can assist brand owners in registering their filer accounts and preparing the necessary documentation.

Q4: How long does it typically take to manufacture a private-label moisturizing and anti-wrinkle eye cream, from sample production to shipment?

A: The standard process is as follows: packaging material confirmation (3–5 days) → sample production and testing (5–7 days) → brand‑side approval (depending on feedback turnaround) → registration testing and documentation preparation (15–20 days) → mass production (7–15 days). If a factory‑ready formula is used and the packaging materials are readily available, the entire timeline can be shortened to 30–35 days; however, if new ingredients or a custom formulation are involved, the lead time extends to 45–60 days. Mingyu’s standard delivery cycle is 7–15 days, with transparent scheduling and the option to reserve production capacity in advance.

Q5: Can the formula of an eye cream be customized? For example, can I specify the concentration of a particular ingredient?

A: Yes, that’s possible. Mingyu supports custom R&D, and our technical team can tailor the formulation to align with the brand’s efficacy objectives, cost constraints, and preferred skin feel. However, two key points should be kept in mind: first, higher concentrations of active ingredients are not always better—balance is essential among transdermal absorption rates, formulation stability, and regulatory restrictions (e.g., retinol and its derivatives have maximum usage limits in leave‑on cosmetics); second, custom formulations must undergo stability testing, preservative challenge testing, and safety assessments, which typically extend the development timeline by 10–15 days compared to established formulas.

Q6: Do the moisturizing and anti-wrinkle claims of the OEM eye cream have test reports? Do I need to submit the product for testing myself?

A: Mingyu Laboratory is equipped with instruments such as HPLC (high-performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry), enabling traceability of raw materials and quantitative analysis of active ingredients. Before products leave the factory, they undergo testing for microbiological parameters, heavy metals, and physicochemical properties. If a brand requires scientific evidence to support efficacy claims—such as human‑subject efficacy evaluations for moisturization or anti‑wrinkle effects—Mingyu can facilitate coordination with third‑party testing laboratories accredited by CMA/CNAS; the associated testing fees are borne by the brand. The facility does not fabricate efficacy reports, and all data are fully traceable.

Q7: I’d like to launch an anti-wrinkle eye cream brand, but I have no experience. Can the factory help me with product registration?

A: Yes, we can. Mingyu offers registration‑agency services that cover formula review, label compliance assessment, preparation of safety evaluation reports, and submission to the registration system. In 2026, the highest rates of registration rejections are concentrated in the areas of safety evaluation reports and evidence supporting efficacy claims; Mingyu’s compliance team conducts upfront reviews to reduce the likelihood of rejection. However, please note that the brand owner, as the party responsible for registration, bears legal liability for the final marketed product, while the manufacturer’s role is technical assistance—not a transfer of responsibility.

III. Summary

When it comes to OEM production of eye creams, brands’ core priority has never been “low cost,” but rather “certainty”—certainty that the formulation can be stably mass‑produced, that regulatory filing will pass on the first attempt, that bulk batches will match the samples, and that delivery will be on time. Over the past 23 years, Mingyu Cosmetics has built flexible manufacturing capacity, a compliant closed-loop system, and deep R&D expertise—essentially hedging against supply‑chain uncertainties for its partner brands. For mid‑to‑high‑end eye‑care brands that prioritize long‑term repeat purchases, choosing a manufacturer that can turn “lab‑tested data” into “consistent, shelf‑ready products” makes far more sense than chasing the lowest price. Market growth is driven by the industry, but brand reputation is earned—and maintained—through one’s own efforts.